Compare Stocks: NVH, DEST, RENE, C4XD, and OBD

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NVH Novoheart	C$0.53 +1.9%	C$0.53	C$0.26 ▼ C$0.72	C$99.98M	N/A	33,593 shs	23,066 shs
RENE Cartesian Growth Co. II	$11.21 +0.1%	$11.11	$10.52 ▼ $11.92	$242.36M	-0.01	27,212 shs	449,602 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NVH Novoheart	0.00%	0.00%	0.00%	0.00%	0.00%
RENE Cartesian Growth Co. II	+0.09%	+0.22%	+0.90%	+1.72%	+6.56%

A new way to collect income from stocks (Ad)

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NVH Novoheart	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NVH Novoheart	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NVH Novoheart	C$423.50K	236.08	C$0.07 per share	7.46	C$0.12 per share	4.34
RENE Cartesian Growth Co. II	N/A	N/A	$0.40 per share	28.14	($0.64) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NVH Novoheart	N/A	-C$0.04	N/A	∞	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	$11.44M	N/A	0.00	∞	N/A	N/A	-65.59%	5.02%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NVH Novoheart	N/A	N/A	N/A	N/A	N/A
RENE Cartesian Growth Co. II	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NVH Novoheart	27.62	6.13	6.05
RENE Cartesian Growth Co. II	N/A	0.22	0.22

Ownership

Institutional Ownership

Company	Institutional Ownership
NVH Novoheart	N/A
RENE Cartesian Growth Co. II	58.96%

Insider Ownership

Company	Insider Ownership
NVH Novoheart	N/A
RENE Cartesian Growth Co. II	20.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
NVH Novoheart	N/A	188.64 million	N/A	Not Optionable
RENE Cartesian Growth Co. II	N/A	21.62 million	17.30 million	Not Optionable

NVH, DEST, RENE, C4XD, and OBD Headlines

Source	Headline
	Short Interest in Cartesian Growth Co. II (NASDAQ:RENE) Increases By 312.5% marketbeat.com - April 25 at 10:22 PM
	Wolverine Asset Management LLC Acquires 104,768 Shares of Cartesian Growth Co. II (NASDAQ:RENE) marketbeat.com - April 23 at 8:48 PM
	Cartesian Growth Co. II (NASDAQ:RENE) Shares Up 0% americanbankingnews.com - April 19 at 2:58 AM
	Cartesian Growth Co. II (NASDAQ:RENE) Short Interest Update marketbeat.com - March 28 at 8:23 PM

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
April 25, 2024 10:36 AM
View Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 3, 2024 6:10 AM
View Biotech Sector Nears Breakout: Will it Outperform in Q2?

All Headlines

Company Descriptions

Novoheart

CVE:NVH

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

Cartesian Growth Co. II

NASDAQ:RENE

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York.

Compare Stocks